Mersaco - News & Release - RYZODEG 70/30


18 May 2016

Ryzodeg is manufactured by Novo Nordisk in Plainsboro, New Jersey, approved by the U.S. Food and Drug Administration (FDA) on September 2015, Launched in Lebanon on the 18th of May 2016, the exclusive distribution across the Lebanese territory is for Mersaco s.a.l.

Over time, diabetes increases the risk of serious health complications, including heart disease, blindness, and nerve and kidney damage. Improvement in blood sugar control can reduce the risk of some of these long-term complications.

Ryzodeg 70/30 is a mixture of insulin degludec, a long-acting insulin analog, and insulin aspart, a rapid-acting human insulin analog. It is indicated to improve glycemic control in adults with diabetes mellitus. Long-acting insulins play an essential role in the treatment of patients with type-1 diabetes and in patients with type-2 diabetes with advanced disease.

Ryzodeg should not be used in those who have increased ketones in their blood or urine (diabetic ketoacidosis).